Corcept

corcept-submitted-lead-asset-for-approval-despite-fda-flagging-risk-of-‘significant-review-issues’

Biotechnology Corcept Uncategorized

Corcept submitted lead asset for approval despite FDA flagging risk of ‘significant review issues’

Jan 30, 2026

The FDA warned Corcept Therapeutics that it would face significant hurdles if it submitted its...

corcept-racks-up-phase-3-cancer-win-to-bounce-back-from-fda-cushing’s-rejection

Biotechnology Corcept Uncategorized

Corcept racks up phase 3 cancer win to bounce back from FDA Cushing’s rejection

Jan 22, 2026

Corcept Therapeutics’ relacorilant has improved overall survival (OS) in a phase 3 ovarian cancer study, building...